Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (BKD) and Coya Therapeutics, Inc. (COYA)

Tipranks - Fri Feb 20, 8:36AM CST

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Brookdale Senior Living (BKDResearch Report) and Coya Therapeutics, Inc. (COYAResearch Report) with bullish sentiments.

President's Day Sale - 70% Off

Brookdale Senior Living (BKD)

Bank of America Securities analyst Joanna Gajuk maintained a Buy rating on Brookdale Senior Living today. The company’s shares closed last Thursday at $15.41.

According to TipRanks.com, Gajuk is a 3-star analyst with an average return of 1.8% and a 56.3% success rate. Gajuk covers the Healthcare sector, focusing on stocks such as Concentra Group Holdings Parent, Inc., BrightSpring Health Services, Inc., and Option Care Health. ;'>

Currently, the analyst consensus on Brookdale Senior Living is a Strong Buy with an average price target of $16.50, which is a -0.4% downside from current levels. In a report released today, Barclays also maintained a Buy rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Coya Therapeutics, Inc. (COYA)

In a report released today, Chad Messer from Lake Street maintained a Buy rating on Coya Therapeutics, Inc., with a price target of $17.00. The company’s shares closed last Wednesday at $4.85, close to its 52-week low of $4.75.

According to TipRanks.com, Messer is a 1-star analyst with an average return of -0.7% and a 36.6% success rate. Messer covers the Healthcare sector, focusing on stocks such as OS Therapies Incorporated, Oncolytics Biotech, and Plus Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Coya Therapeutics, Inc. with a $17.00 average price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.